CAP24 Paddle Lead, Passing Elevator, Evoke CLS (REF 3042), Clarity Programming Application (CPA), and RECAP Viewer
Saluda Medical Pty, Ltd. · Decision date Jun 29, 2026
What did the FDA approve?
FDA records P190002/S039 as a supplement to PMA P190002, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Jun 29, 2026.
FDA approval order statement
Approval for the CAP24 Paddle Lead and Passing Elevator components, software updates to the Clarity Clinical Programming Application (CPA) and RECAP Viewer (CDV) to support the CAP24 Paddle Lead and include minor bug fixes and improvements, and labeling updates to support these changes. Software changes required for use of the paddle lead with the Evoke Spinal Cord Stimulation (SCS) System were also approved in P190002/S038.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Neurology
- Decision date
- Jun 29, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P190002/S039
- Regulatory pathway
- PMA supplement
- Applicant
- Saluda Medical Pty, Ltd.
- Product code
- LGW
- Decision code
- APPR
- Decision date
- Jun 29, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.
- Applicant
- Saluda Medical Pty, Ltd.
- Product code
- LGW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P190002. Subsequent supplements may change the device or its indications.
FDA decision timeline
P190002 · Original PMA
Saluda Medical Evoke SCS System
P190002/S039 received
Application receipt date recorded by FDA.
P190002/S041 · Related supplement
Saluda Medical Evoke SCS System
P190002/S045 · Related supplement
Saluda Medical Evoke SCS System
P190002/S036 · Related supplement
Saluda Medical Evoke SCS System
P190002/S048 · Related supplement
Evoke SCS System
P190002/S049 · Related supplement
Saluda Medical Evoke SCS System
P190002/S038 · Related supplement
Saluda Medical Evoke SCS System; Closed Loop Stimulator (CLS) (REF: 3042)
P190002/S039 · FDA decision
Normal 180 Day Track
P190002/S051 · Related supplement
Saluda Medical Evoke SCS System
P190002/S052 · Related supplement
Saluda Medical Evoke SCS System
Timeline entries are records held by MedtechLedger for P190002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Saluda Medical Pty, Ltd. | PMA approval | Feb 28, 2022 | FDA | |
Saluda Medical Evoke SCS SystemP190002/S041 | Saluda Medical Pty, Ltd. | PMA supplement | Aug 21, 2025 | FDA |
Saluda Medical Evoke SCS SystemP190002/S045 | Saluda Medical Pty, Ltd. | PMA supplement | Nov 8, 2025 | FDA |
Saluda Medical Evoke SCS SystemP190002/S036 | Saluda Medical Pty, Ltd. | PMA supplement | Jan 6, 2026 | FDA |
Evoke SCS SystemP190002/S048 | Saluda Medical Pty, Ltd. | PMA supplement | Jun 12, 2026 | FDA |
Saluda Medical Evoke SCS SystemP190002/S049 | Saluda Medical Pty, Ltd. | PMA supplement | Jun 12, 2026 | FDA |
| Saluda Medical Pty, Ltd. | PMA supplement | Jun 29, 2026 | FDA | |
Saluda Medical Evoke SCS SystemP190002/S051 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 15, 2026 | FDA |
Saluda Medical Evoke SCS SystemP190002/S052 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 16, 2026 | FDA |
Explore the linked device profile
Other records with product code LGW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Saluda Medical Pty, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Level 1, 407 Pacific Hwy., Atarmon, NSW 2064
Sources and methodology
- Original FDA record: P190002/S039
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





